Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D01FDN
|
|||
Former ID |
DIB015108
|
|||
Drug Name |
NAL-GLU
|
|||
Synonyms |
[Ac-D2Nal1,D4ClPhe2,D3Pal3,Arg5,DGlu5(anisole adduct),DAla10]-GnRH; Acetyl-D-2-naphthylalanyl-D-4-chlorophenylalanyl-D-3-pyridylalanyl-L-seryl-L-arginyl-[4-(4-methoxybenzoyl)-D-2-aminobutyryl]-L-leucyl-L-arginyl-L-prolyl-D-alanylamide; N-Acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-arginyl-5-(4-methoxyphenyl)-5-oxo-D-norvalyl-L-leucyl-L-arginyl-L-prolyl-D-alanylamide
Click to Show/Hide
|
|||
Indication | Prostate cancer [ICD-11: 2C82.0; ICD-10: C61; ICD-9: 185] | Phase 2/3 | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C18H21N3O4
|
|||
Canonical SMILES |
C1=CC=C2C=C(C=CC2=C1)CC(C(=O)NC(CCC(=O)N)C(=O)O)N
|
|||
InChI |
1S/C18H21N3O4/c19-14(17(23)21-15(18(24)25)7-8-16(20)22)10-11-5-6-12-3-1-2-4-13(12)9-11/h1-6,9,14-15H,7-8,10,19H2,(H2,20,22)(H,21,23)(H,24,25)/t14-,15-/m0/s1
|
|||
InChIKey |
VSZVSSYQFUFEQG-GJZGRUSLSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Leutinizing-hormone-releasing hormone (GNRH1) | Target Info | . | [2] |
KEGG Pathway | GnRH signaling pathway | |||
Pathway Interaction Database | Nongenotropic Androgen signaling | |||
Reactome | Hormone ligand-binding receptors | |||
G alpha (q) signalling events | ||||
WikiPathways | Gastrin-CREB signalling pathway via PKC and MAPK | |||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT00351416) Letrozole Treatment in Normal and GnRH Deficient Women. U.S. National Institutes of Health. | |||
REF 2 | The gonadotropin-releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women. Am J Obstet Gynecol. 1991 Dec;165(6Pt 1):1811-7. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.